PCSK9 Inhibitors: A New Frontier in Preventing First Heart Attacks and Strokes?
New data presented at the American College of Cardiology 2026 Scientific Session is challenging conventional wisdom about who benefits from aggressive cholesterol-lowering therapy. A subgroup analysis of the VESALIUS-CV trial reveals that adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to statin therapy significantly reduces the risk of major cardiovascular events even in high-risk patients without prior heart attack or stroke.
Beyond Secondary Prevention: Lowering the Bar for LDL Targets
For years, the most intensive LDL-cholesterol targets – typically below 55 mg/dL – have been reserved for patients who have already experienced a cardiovascular event. However, the VESALIUS-CV findings suggest this approach may be too conservative for individuals at high risk of a first event, particularly those with diabetes. Investigators are now suggesting targets as low as 40 mg/dL in high-risk diabetic patients without known atherosclerosis may be appropriate.
“We are currently using evolocumab for patients with high-risk atherosclerosis, so this subgroup with no known atherosclerosis is really a novel group,” explained Dr. Nicholas Marston of Brigham and Women’s Hospital, Boston, MA, who led the analysis. This shift in thinking could have significant implications for treatment guidelines.
VESALIUS-CV: The Data Behind the Change
The VESALIUS-CV trial included over 12,000 high-risk patients – those with diabetes plus a cardiovascular risk enhancer, or atherosclerosis with or without diabetes and elevated LDL cholesterol. The analysis focused on 3,365 patients with diabetes but no evidence of atherosclerosis. Those treated with evolocumab in addition to statins experienced a 59 mg/dL reduction in LDL cholesterol after 48 weeks, reaching a median level of 52 mg/dL. At 96 weeks, the median LDL in the evolocumab group was even lower, at 44 mg/dL.
The results were compelling: a 2.1% absolute reduction in the risk of a three-point MACE (coronary heart disease death, MI, or ischemic stroke) over five years with evolocumab. The risk of a four-point MACE, including ischemia-driven revascularization, was reduced by 2.9%. Importantly, both all-cause and cardiovascular mortality were likewise significantly lower in the evolocumab group.
The Cost-Effectiveness Question: PCSK9 Inhibitors vs. Ezetimibe
While the VESALIUS-CV data is promising, the higher cost of PCSK9 inhibitors compared to other cholesterol-lowering drugs, like ezetimibe, remains a significant barrier to widespread adoption. Experts acknowledge that ezetimibe is a more cost-effective strategy and may be sufficient to reach LDL targets of less than 70 mg/dL in some patients.
However, Dr. Marston points out that ezetimibe may not be enough to achieve the more aggressive targets now being considered for high-risk individuals. “It’s not going to acquire you to the goal, to the guideline-directed target of less than 70 mg/dL, on average, in that group,” he stated. “Sometimes we just need a larger benefit or larger reduction with your drug.”
A Shift in Prevention: Lower is Better, Even Early On
Dr. Ann Marie Navar of UT Southwestern Medical Center, Dallas, TX, highlighted a growing awareness that “lower is better” when it comes to LDL cholesterol, even in primary prevention. The challenge now lies in translating this understanding into clinical practice.
John D. Bucheit, PharmD, of Virginia Commonwealth University, Richmond, emphasized the need to re-examine LDL targets for high-risk primary prevention patients. He expressed hope that the VESALIUS-CV findings will lead to improved insurance coverage for PCSK9 inhibitors.
Did you know? The 2026 dyslipidemia guidelines recommend a target LDL cholesterol of less than 100 mg/dL for patients with diabetes but no clinical atherosclerotic cardiovascular disease (ASCVD).
The Road Ahead: Integrating New Evidence into Practice
The findings from VESALIUS-CV weren’t incorporated into the recently released 2026 dyslipidemia guidelines, as the trial data became available after the guidelines were finalized. However, the guidelines’ writing committee acknowledged the trial’s evidence supporting more intensive lipid-lowering targets in high-risk patients with diabetes.
The key takeaway is that a more proactive approach to cardiovascular risk reduction may be warranted for a broader range of patients than previously thought. As Dr. Marston noted, PCSK9 inhibitors have been available for over a decade, but their uptake in clinical practice has been unhurried. He hopes this new analysis will encourage wider use of these powerful medications, particularly in primary care and other specialties.
Frequently Asked Questions
Q: What are PCSK9 inhibitors?
A: PCSK9 inhibitors are a class of drugs that lower LDL cholesterol by blocking a protein called PCSK9, which prevents the liver from removing LDL cholesterol from the blood.
Q: Who is considered “high-risk” for cardiovascular disease?
A: High-risk individuals typically include those with diabetes, multiple cardiovascular risk factors (like high blood pressure and smoking), or a family history of heart disease.
Q: Are PCSK9 inhibitors right for everyone?
A: No. They are generally reserved for patients who haven’t reached their LDL cholesterol goals with statins and other therapies, and who are at high risk of cardiovascular events.
Q: What is MACE?
A: MACE stands for Major Adverse Cardiovascular Events, and typically includes heart attack, stroke, and cardiovascular death.
Pro Tip: Talk to your doctor about your individual cardiovascular risk factors and whether PCSK9 inhibitors or other cholesterol-lowering therapies might be right for you.
Want to learn more about managing your heart health? Explore our other articles on cardiovascular disease prevention.
